汪俊 博士
上海s36沙龙会生物医药股份有限公司生物部副总裁

汪俊博士毕业于上海复旦大学，在日本神户大学获分子生物学和生物化学博士学位，在美国达拉斯德州大学西南医学中心药理学院完成了博士后研究。汪博士在美国德州大学西南医学中心和华盛顿大学担任了5年助教授；在默沙东公司（Merck）工作了9年，担任课题总负责人；在Nature、Science等权威科学杂志上发表过多篇论文和专利，目前受聘于四个国际期刊的编委。作为新抗菌素--平板霉素和平板素的发现人，汪博士曾受邀英国剑桥大学和皇家化学会等多学府及科研机构进行学术演讲。2010年汪俊博士加入s36沙龙会，担任生物研发部的副总裁。

牛俊奇 博士
吉林大学第一医院肝病中心主任

主任医师，教授，医学博士,博士生导师，国务院特殊津贴专家。吉林大学转化医学研究院副院长, 吉林省肝病研究所所长，吉林大学第一医院肝胆胰内科主任，吉林大学第一医院临床药理机构主任，吉林大学第一医院感染性疾病诊治中心主任，《临床肝胆病杂志》主编，中国科学院上海巴斯德研究所和北华大学特聘教授，吉林省肝脏病学会委员会主任委员，吉林省传染病学会名誉主任委员，亚洲及太平洋地区肝病学会会员，欧洲肝病学会会员，美国肝病学会会员。并担任国内外数十家杂志的编委委员，近年来在Hepatology，J Gastroenterol. Antiviral Res.  J Med Virol.等发表SCI检索的论文四十多篇。最高影响因子11.665。先后承担了“十一五”、“十二五”国家科技重大专项、863、973、国家自然科学基金等多项科研项目。擅长病毒性肝炎,以及其他各类肝病、消化疾病的诊断及治疗。获卫生部有突出贡献中青年专家、吉林省资深高级专家、中华医学科技二等奖、吉林大学白求恩十大名医等荣誉称号。

Qun (Max) Dang, Ph.D.
Principal Scientist, Exploratory Chemistry
Merck Research Laboratories

Qun (Max) Dang obtained his B.S. degree in chemistry in 1985 from Jilin University and Ph.D. in chemistry from Purdue University in 1992 (under a CGP scholarship).  Max joined Gensia pharmaceuticals (later became Metabasis) in 1992 and worked until 2009 with his last position as director of medicinal chemistry. In 2009, Max joined the External Basic Research department of Merck Rahway site as a Senior Investigator; from 2011 to 2013, he was a Director of External Medicinal Chemistry based in Shanghai and currently he is a Principal Scientist of Exploratory Chemistry department at the Kenilworth site.

During his time at Metabasis, Max managed multiple drug discovery projects primarily in metabolic disease areas such as diabetes and dyslipidemia (such as FBPase inhibitors, glucagon antagonists, glucokinase activators, and AMPK activators). He also conducted researches in liver related disease such as hepatitis B, hepatitis C, liver cancer, liver fibrosis. Max's work at Metabasis led to two NCEs advancing to phase IIb clinical trials as potential treatment of type 2 diabetes.

Since joining Merck in 2009, Max managed several integrated drug discovery projects carried out at various CROs in the areas of infectious disease and endocrine. His research interests include medicinal chemistry via rational drug design, heterocyclic chemistry, prodrugs, and nucleoside chemistry. Dr. Dang has authored or co-authored 84 publications in peer-reviewed journals, 2 book chapters, and 50 granted patents and applications.